DarioHealth Corp. (NASDAQ:DRIO) Short Interest Up 47.3% in March

DarioHealth Corp. (NASDAQ:DRIO) was the target of a large increase in short interest in March. As of March 31st, there was short interest totaling 66,009 shares, an increase of 47.3% from the March 15th total of 44,799 shares. Approximately 0.9% of the company’s stock are sold short. Based on an average daily volume of 14,444 shares, the short-interest ratio is presently 4.6 days.

Hedge Funds Weigh In On DarioHealth

Several institutional investors and hedge funds have recently bought and sold shares of DRIO. Kestra Advisory Services LLC purchased a new position in DarioHealth during the fourth quarter valued at $35,000. XTX Topco Ltd lifted its position in DarioHealth by 229.0% during the second quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock valued at $42,000 after purchasing an additional 43,513 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in DarioHealth by 167.9% during the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after purchasing an additional 31,063 shares in the last quarter. 33.39% of the stock is currently owned by hedge funds and other institutional investors.

DarioHealth Stock Performance

Shares of DRIO traded down $0.05 during trading hours on Wednesday, hitting $7.51. The stock had a trading volume of 39,906 shares, compared to its average volume of 15,352. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.76 and a quick ratio of 3.30. DarioHealth has a 12 month low of $5.93 and a 12 month high of $17.74. The firm has a market capitalization of $54.82 million, a PE ratio of -0.72 and a beta of 1.28. The stock has a fifty day moving average price of $9.33 and a 200 day moving average price of $11.58.

Analysts Set New Price Targets

Several brokerages recently commented on DRIO. Stifel Nicolaus cut their price objective on DarioHealth from $16.00 to $10.00 and set a “buy” rating for the company in a report on Friday, March 20th. Wall Street Zen lowered DarioHealth from a “hold” rating to a “sell” rating in a report on Sunday, January 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DarioHealth in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $35.00.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.